Inhibitors of bruton's tyrosine kinase
US8399470B2 · kind B2 · utility
56Cited by
14References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 30, 2012 |
| Grant date | Mar 19, 2013 |
| Priority date | — |
| Expiry date | Jan 30, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are pyrazolo[3,4-d]pyrimidines that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.